Omeros Corp Announces $16.2 Million Registered Direct Offering Of Common Stock

Thursday, 9 May 2013 06:31pm EDT 

Omeros Corp announced that it has agreed to sell 3,903,004 shares of common stock at a price of $4.14 per share, a 2% premium over the closing price on May 8, 2013, for gross proceeds of $16.2 million. The shares were offered and are expected to be sold to RA Capital Management and other investors in a registered direct offering conducted without an underwriter or placement agent. The net proceeds from the offering, after deducting estimated offering expenses, will be approximately $16.1 million. The offering is expected to close on or about May 14, 2013. Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for research and development expenses, such as funding planned clinical trials for OMS103HP, PDE10, MASP-2 and PDE7 programs. The net proceeds may also be used to fund pre-clinical studies, capital expenditures, working capital and to otherwise advance Omeros' potential products towards commercialization. 

Company Quote

-0.35 -1.42%
24 Apr 2015